Novel aminoacids derivatives, their process of preparation and their therapeutical uses as MET inhibitors

The invention relates to novel imidazobenzothiazole amino acid derivs. I [the arom. rings may be substituted; R = H or halo; R1 = H, alkyl, aryl, alkylaryl; R2 = H, alkyl, alkylaryl; X, Y = (un)substituted alkyl, cycloalkyl, aryl, alkylaryl, heteroaryl; X may also be H], either as racemic mixts. or enantiomers and pharmaceutically-acceptable salts, and includes the process for their prepn. and their use for inhibiting Met-triggered disorders, in particular cancer. Thus, I [R = R1 = R2 = H; CO(CH2)0-1CH[(CH2)0-2-X]NR2 = L-Phe; Y = 3,5-dimethylbenzyl] (II) was prepd. by acylation of (S)-2-[(3,5-dimethylphenyl)acetamido]-3-phenylpropanoic acid with 4-(imidazo[2,1-b]benzothiazol-2-yl)aniline. Compds. of the invention were submitted to a biol. screening of cell motility, namely scattering response, with II having IC50 scattering inhibition = 100-300 nM and no toxicity at 300 μM. Compds. of formula I interfere with Met-triggered tumorigenesis in vitro.